SL
AMRX icon

Salomon & Ludwin’s Amneal Pharmaceuticals AMRX Stock Holding History

Salomon & Ludwin’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.1K Buy
711
+515
+263% +$7.06K ﹤0.01% 1500
2026
Q1 		$2.45K Buy
+196
New +$2.63K ﹤0.01% 1909

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Salomon & Ludwin's AMRX Position: Q2 2026 in Review

Salomon & Ludwin increased its Amneal Pharmaceuticals (AMRX) stake by 263% in Q2 2026, buying an estimated $7.06K and bringing the position to 711 shares worth $12.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1500.

Salomon & Ludwin first reported a position in AMRX in Q1 2026 and has held it in 2 quarters since. 310 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Salomon & Ludwin held 711 shares of Amneal Pharmaceuticals worth $12.1K as of Q2 2026.
  • Salomon & Ludwin bought 515 Amneal Pharmaceuticals shares in Q2 2026, an estimated $7.06K.
  • Amneal Pharmaceuticals made up ﹤0.01% of Salomon & Ludwin's portfolio in Q2 2026, its #1500 holding.
  • Salomon & Ludwin first reported a position in Amneal Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 310 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Salomon & Ludwin's 13F filing for Q2 2026, filed 7 Aug 2026.